HLS ASX: Australia's No.2 player in pathology, Healius, face

There’s restructuring ahead at the No. 2 pathology provider Healius, which despite its activist ructions, has yielded a 30 per cent return since its 2023 low.

Related Keywords

Northern Territory , Australia , South Africa , Australian , David Kingston , Ravi Jeyaraj , Michael Alscher , Michael Stanford , Kate Mckenzie , John Wylie , Agilex Biolabs , Craig Wong Pan , Jan Van Rooyen , Maple Brown Abbott , Sean Laaman , David Stanton , Morgan Stanley , Phlebotomists Council Of Australia , Consumer Commission , Australian Retirement , Tanarra Capital , Australian Retirement Trust , Australian Clinical Labs , Australian Competition , Western Australia , Dorevitch Pathology , Laverty Pathology , Abbott Pathology , Medicare Benefits Schedule , Lumus Imaging , Phlebotomists Council ,